- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07759154
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
A Phase 3b, Multicenter, Open-label, Single-arm Trial to Evaluate the Efficacy and Safety of Orally Administered Centanafadine QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: otsuka-professionalservices@otsuka-us.com
Studie Locaties
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32607
- Werving
- Sarkis Clinical Trials - Gainesville
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Sarkis
-
Jacksonville, Florida, Verenigde Staten, 32256
- Werving
- CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)
-
Hoofdonderzoeker:
- Jones
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Maitland, Florida, Verenigde Staten, 32751
- Werving
- Accel Research Sites-Maitland
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Marraffino
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70125
- Werving
- Nola Research Works
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Hebert
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02132
- Werving
- Boston Clinical Trials
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Mezhebovsky
-
Watertown, Massachusetts, Verenigde Staten, 02472
- Werving
- Adams Clinical - Watertown
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Rutrick
-
-
Missouri
-
Saint Charles, Missouri, Verenigde Staten, 63304
- Werving
- St. Charles Psychiatric Associates/Midwest Research Group
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Mattingly
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89128
- Werving
- Center for Psychiatry and Behavioral Medicine. Inc.
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Childress
-
-
New Jersey
-
Cherry Hill, New Jersey, Verenigde Staten, 08002
- Werving
- Center for Emotional Fitness
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Corcoran
-
-
New York
-
New York, New York, Verenigde Staten, 10128
- Werving
- The Medical Research Network, LLC
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Careri
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45215
- Werving
- Patient Priority Clinical Trials
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Popovitz
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97210
- Werving
- Summit Research Network
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Essink
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78737
- Werving
- Donald J. Garcia, Jr, MD, PA
-
Hoofdonderzoeker:
- Garcia
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Bellaire, Texas, Verenigde Staten, 77401
- Werving
- Houston Clinical Trials LLC
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Katic
-
Houston, Texas, Verenigde Staten, 77089
- Werving
- Kaleidoscope Clinical Research
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Higgins
-
-
Washington
-
Everett, Washington, Verenigde Staten, 98201
- Werving
- Core Clinical Research
-
Contact:
- Otsuka Call Center
- Telefoonnummer: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Hoofdonderzoeker:
- Knutson
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria
- Primary diagnosis of ADHD per the Adult ADHD Clinical Diagnostic Scale (ACDS).
- Adult ADHD Investigator Symptom Rating Scale (AISRS) total score of ≥ 28 at baseline.
- Symptoms of ED as determined by the WRAADDS-ED subscale score ≥ 7 at baseline.
- CGI-S-ADHD rating ≥ 4 (at least moderate severity) at baseline.
Exclusion Criteria
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for a lifetime diagnosis of bipolar and related disorders, schizophrenia spectrum and other psychotic disorders, borderline and antisocial personality disorders, neurocognitive disorders, autism spectrum disorder, or intellectual disability.
- DSM-5 criteria for a current diagnosis of major depressive disorder, post-traumatic stress disorder, any substance use disorder, untreated/unstable obstructive sleep apnea, eating disorders, or obsessive compulsive disorder.
- Any other current DSM-5 comorbid psychiatric disorder identified by the Mini International Neuropsychiatric Interview (MINI) or any medical condition that, in the judgment of the investigator, could be expected to require treatment with medications prohibited in this trial that cannot be safely discontinued with completion of an appropriate washout, could confound efficacy or safety assessments, or be the primary driver of ED.
- Presence of an unstable or uncontrolled medical condition that, in the opinion of the investigator, could pose a safety risk to the participant or could manifest with psychiatric symptoms (eg, thyroid disease).
- In the clinical opinion of the investigator, the participant has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate, or amphetamine and atomoxetine) given with an acceptable dose and duration during adulthood (aged 18 years or older).
- Current use of prohibited psychotropic medications that cannot be discontinued within 7 to 28 days prior to enrollment.
- Any disorder that is the primary focus of treatment other than ADHD.
- Evidence of current substance use disorder or history in the past 12 months.
- History of any prior exposure to centanafadine.
- Participated in other clinical trials involving investigational drugs within 180 days prior to screening or participated in more than 2 interventional clinical trials involving investigational drugs within the past year.
- Have an allergy to the IMP or any component of the IMP.
Note: Other protocol-specified inclusion/exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Centanafadine XR
Participants will receive centanafadine XR capsule 328.8 milligrams (mg), orally, QD, for 8 weeks. |
Oral capsules
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation (WRAADDS-ED) Subscale Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity Scale for Attention-Deficit/Hyperactivity Disorder (CGI-S-ADHD) Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) T-score for the Global Executive Composite (GEC) Scale
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Behavioral Regulation Index (BRI) Scale
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Metacognition Index (MI) Scale
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties in Emotion Regulation Scale (DERS) Total Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Nonacceptance of Emotional Responses (NONACCEPT) DERS Subscale Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties Engaging in Goal-Directed Behavior (GOALS) DERS Subscale Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Impulse Control Difficulties (IMPULSE) DERS Subscale Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Awareness (AWARE) DERS Subscale Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Limited Access to Emotion Regulation Strategies (STRATEGIES) DERS Subscale Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Clarity (CLARITY) DERS Subscale Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Attention-Deficit/Hyperactivity Disorder Symptoms, Executive Function Deficits, and Emotional Dyscontrol as Assessed by the Adult ADHD Self-Report Scale (ASRS) Score
Tijdsspanne: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Number of Participants With Adverse Events
Tijdsspanne: Up to Week 9
|
Up to Week 9
|
|
Number of Participants With Suicidal Ideation or Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tijdsspanne: Up to Week 9
|
Up to Week 9
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 405-201-00231
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD-tijdsbestek voor delen
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD-toegangscriteria voor delen
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .